Perkins, Andrew
The Alfred Hospital · Monash University
6 papers on CoChatORCID 0000-0003-3644-7093
Most cited papers
- Verified
Stem cell transcriptome profiling via massive-scale mRNA sequencing
Cloonan, N., Forrest, A. R. R., Kolle, G., Gardiner, B. B. A., Faulkner, G. J., Brown, M. K., Taylor, D. F., Steptoe, A. L., Wani, S., Bethel, G., et al. (2008) · Nature Methods
Genomics and Phylogenetic StudiesSingle-cell and spatial transcriptomics
Cited by 1,035
- Verified
Isolation and characterization of the cDNA encoding BKLF/TEF-2, a major CACCC-box-binding protein in erythroid cells and selected other cells
Crossley, M., Whitelaw, E., Perkins, A., Williams, G., Fujiwara, Y., & Orkin, S. H. (1996) · Molecular and Cellular Biology
Kruppel-like factors researchGenomics and Chromatin Dynamics
Cited by 222
- Verified
Complex architecture and regulated expression of the Sox2ot locus during vertebrate development
Amaral, P. P., Neyt, C., Wilkins, S. J., Askarian-Amiri, M. E., Sunkin, S. M., Perkins, A. C., & Mattick, J. S. (2009) · RNA
Developmental Biology and Gene RegulationCancer-related molecular mechanisms research
Cited by 209
- Verified
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis
Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 41
- Verified
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 17
- Verified
Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis
Mascarenhas, J. O., Bose, P., Hou, H.-A., Homenda, W., Ross, D., Mohan, S. R., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Khalina, Y., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free